Phase 3 DECISION Trial of Nexavar Meets Primary Endpoint

Bayer HealthCare Pharmaceuticals (OTC: BAYRY ) and Onyx Pharmaceuticals (NASDAQ: ONXX ) today announced that a Phase 3 trial of Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free